Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.53 |
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5769402 | 0.86 | CA12 (0.44) | ALDH1A1 | |
| SCHEMBL5770188 | 0.82 | ESR2 (0.47) | ALPLESR1ESR2HDAC4HDAC2 | |
| SCHEMBL5946257 | 0.81 | MAPT (0.47) | ALDH1A1HPGDHSD17B10 | |
| SCHEMBL5768982 | 0.78 | ALDH2 (0.42) | ALDH1A1CYP1A2HPGDERN1 | |
| SCHEMBL3493408 | 0.75 | HTT (0.46) | SLC6A3ALDH1A1CYP1A2 | |
| SCHEMBL27962543 | 0.73 | HDAC4 (0.43) | SLC6A3SLC6A4SLC6A2ALPLESR1 | |
| SCHEMBL5946221 | 0.71 | SLC6A3 (0.47) | SLC6A3SLC6A4SLC6A2ALPLESR1 | |
| SCHEMBL16112588 | 0.70 | HTT (0.52) | SLC6A3ALDH1A1HPGDHSD17B10 | |
| SCHEMBL16683936 | 0.70 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2ALPLHDAC4 | |
| SCHEMBL16111747 | 0.69 | LMNA (0.48) | SLC6A3SLC6A4ALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287529-A1 | Solid phase synthesis of antitumoral compounds | PHARMA MAR, S.A.U. (ES) | 2006-12-21 | — | — | US | disclosed |
| EP-1613635-A2 | SOLID PHASE SYNTHESIS OF ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004073598-A2 | SOLID PHASE SYNTHESIS OF ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A.U. (ES) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287529-A1 | Solid phase synthesis of antitumoral compounds | TSNAX, TSN, PLIN5 | SLC6A3 3807/4885SLC6A4 4447/4885SLC6A2 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.